Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based study

Howard J Lim; Sharlene Gill; Caroline Speers; Barbara Melosky; Jeff Barnett; Catherine Fitzgerald; Susan O'Reilly; Hagen Kennecke

doi:10.1200/JOP.0942001

Impact of irinotecan and oxaliplatin on overall survival in patients with metastatic colorectal cancer: a population-based study

J Oncol Pract. 2009 Jul;5(4):153-8. doi: 10.1200/JOP.0942001.

Authors

Howard J Lim¹, Sharlene Gill, Caroline Speers, Barbara Melosky, Jeff Barnett, Catherine Fitzgerald, Susan O'Reilly, Hagen Kennecke

Affiliation

¹ Division of Medical Oncology; and Population and Preventive Oncology, British Columbia Cancer Agency, Vancouver; and Division of Medical Oncology, British Columbia Cancer Agency, Victoria, British Columbia, Canada.

Abstract

A look at the temporal impact of advancements in therapeutic options in the last 10 years-from fluorouracil to irinotecan and oxaliplatin-on overall survival in a population-based cohort.